NASDAQ:ASBP News 11 November 2025 - 15 December 2025

Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is stepping into December 15, 2025 with a very “micro-cap biotech” mix of catalysts and pressure points: a Nasdaq deadline calendar, an FDA regulatory milestone for its lead sublingual aspirin program, and capital-structure dynamics that can swing sentiment fast. ASBP shares were trading around $0.095 as of mid-morning UTC on December 15, 2025 (down roughly 8% on the session at that timestamp). That sub‑$0.10 neighborhood matters—not as a psychological trivia point, but because the company is actively working through Nasdaq continued-listing requirements and a recapitalization narrative that’s hard to ignore. Barchart.com+1 Below is a

Micro‑cap biotech Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) is back in the spotlight today after securing a new $100 million equity line of credit and releasing its Q3 2025 10‑Q, sending the stock sharply higher in pre‑market trading. ASBP stock among Friday’s biggest pre‑market movers Aspire Biopharma shares were one of the most active health‑care names in U.S. pre‑market trade on Friday. StockTitan data places Aspire’s current market capitalization at roughly $5.3 million, with a public float of about 27.2 million shares and insider ownership above 30%.Stock Titan Today’s move comes as investors digest two major disclosures: a fresh $100

What moved ASBP today (Nov. 11) Trading in Aspire Biopharma swung sharply. A pre‑market “health‑care movers” screen showed ASBP briefly up more than 30%, before regular‑session selling pulled shares lower on very heavy volume. Mid‑session, ASBP was down roughly 20–25% versus Monday’s close, with an exceptionally wide intraday range—characteristic of micro‑cap names facing near‑term listing and financing milestones. Benzinga While price action is noisy, there were no fresh corporate announcements today. The latest company communication remains last week’s trade‑show recap from CPHI Frankfurt, where Aspire says it held 16 formal meetings and multiple informal conversations with global pharmas regarding potential